Immuneering Leads The Pack Of 3 US Penny Stocks To Monitor [Yahoo! Finance]
Immuneering Co. (NASDAQ: IMRX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $13.00 price target on the stock.
Immuneering Co. (NASDAQ: IMRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $15.00 price target on the stock.
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
Immuneering rises on orphan drug designation for treatment of pancreatic cancer [Seeking Alpha]